2.15

3.86% +0.08

Invivyd Inc (IVVD)

Overview News Price History Option Chain Discussions Forecast

Invivyd Inc stock is currently priced at $2.15, with a 24-hour trading volume of 323.79K. It has seen a +3.86% increased in the last 24 hours and a -41.26% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.06 pivot point. If it approaches the $2.16 resistance level, significant changes may occur.

Previous Close:

$2.07

Open:

$2.06

24h Volume:

323.79K

Market Cap:

$256.33M

Revenue:

Net Income/Loss:

$-198.64M

P/E Ratio:

-1.3354

EPS:

-1.61

Net Cash Flow:

$-173.78M

1W Performance:

-6.52%

1M Performance:

-41.26%

6M Performance:

+29.52%

1Y Performance:

+97.25%

1D Range:

$2.06

$2.23

52W Range:

$0.9802

$5.195

Invivyd Inc Stock (IVVD) Company Profile

Name

Invivyd Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

781 819 0080

Address

1601 Trapelo Road, Suite 178, Waltham

Employee

101

Twitter

Next Earnings Date

Latest SEC Filings

IVVD's Discussions on Twitter

Invivyd Inc Stock (IVVD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
May-01-23	Initiated	H.C. Wainwright	Buy

Invivyd Inc Stock (IVVD) Latest News

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

GlobeNewswire Inc.

Invivyd Announces CEO Transition

GlobeNewswire Inc.

Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session

Benzinga

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

GlobeNewswire Inc.

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire Inc.

Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Invivyd Inc Stock (IVVD) Financials Data

Invivyd Inc (IVVD) Net Income 2024

IVVD net income (TTM) was -$198.64 million for the quarter ending December 31, 2023, a +17.68% increase year-over-year.

Invivyd Inc (IVVD) Cash Flow 2024

IVVD recorded a free cash flow (TTM) of -$173.78 million for the quarter ending December 31, 2023, a +21.00% increase year-over-year.

Invivyd Inc (IVVD) Earnings per Share 2024

IVVD earnings per share (TTM) was -$1.81 for the quarter ending December 31, 2023, a +18.83% growth year-over-year.

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.